Brosa M - Search Results

1

Clinical and cost effectiveness of sacral nerve stimulation for faecal incontinence.

Muñoz-Duyos A, Navarro-Luna A, Brosa M, Pando JA, Sitges-Serra A, Marco-Molina C. Muñoz-Duyos A, et al. Among authors: brosa m. Br J Surg. 2008 Aug;95(8):1037-43. doi: 10.1002/bjs.6140. Br J Surg. 2008. PMID: 18574847

2

Cost-effectiveness analysis of sacral neuromodulation (SNM) with Interstim for fecal incontinence patients in Spain.

Brosa M, Muñoz-Duyos A, Navarro-Luna A, Rodriguez JM, Serrano D, Gisbert R, Dziekan K, Segú JL. Brosa M, et al. Curr Med Res Opin. 2008 Mar;24(3):907-18. doi: 10.1185/030079908X260970. Epub 2008 Feb 14. Curr Med Res Opin. 2008. PMID: 18279582

3

Cost-effectiveness of sacral neuromodulation compared to botulinum neurotoxin a or continued medical management in refractory overactive bladder.

Arlandis S, Castro D, Errando C, Fernández E, Jiménez M, González P, Crespo C, Staeuble F, Rodríguez JM, Brosa M. Arlandis S, et al. Among authors: brosa m. Value Health. 2011 Mar-Apr;14(2):219-28. doi: 10.1016/j.jval.2010.08.006. Value Health. 2011. PMID: 21402292 Free article.

4

Sacral neuromodulation for the treatment of fecal incontinence: analysis of cost-effectiveness.

Indinnimeo M, Ratto C, Moschella CM, Fiore A, Brosa M, Giardina S. Indinnimeo M, et al. Among authors: brosa m. Dis Colon Rectum. 2010 Dec;53(12):1661-9. doi: 10.1007/DCR.0b013e3181f46309. Dis Colon Rectum. 2010. PMID: 21178862

5

Development of a population-based cost-effectiveness model of chronic graft-versus-host disease in Spain.

Crespo C, Pérez-Simón JA, Rodríguez JM, Sierra J, Brosa M. Crespo C, et al. Among authors: brosa m. Clin Ther. 2012 Aug;34(8):1774-87. doi: 10.1016/j.clinthera.2012.06.029. Epub 2012 Jul 25. Clin Ther. 2012. PMID: 22835778 Free article.

6

Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B.

Buti M, Brosa M, Casado MA, Rueda M, Esteban R. Buti M, et al. Among authors: brosa m. J Hepatol. 2009 Oct;51(4):640-6. doi: 10.1016/j.jhep.2009.04.013. Epub 2009 May 20. J Hepatol. 2009. PMID: 19576651

7

Cost-effectiveness analysis of 5-fluorouracil 0.5%/salicylic acid 10% in the treatment of actinic keratosis in Spain.

Nieves D, Puig-Peiró R, Ferrándiz C, Plazas MJ, Brosa M. Nieves D, et al. Among authors: brosa m. Expert Rev Pharmacoecon Outcomes Res. 2015 Jun;15(3):539-43. doi: 10.1586/14737167.2015.995171. Epub 2014 Dec 13. Expert Rev Pharmacoecon Outcomes Res. 2015. PMID: 25495775

8

Cost-Effectiveness and Clinical Impact of Antiviral Strategies of HBeAg-Positive and -Negative Chronic Hepatitis B.

Oyagüez I, Buti M, Brosa M, Rueda M, Casado MA. Oyagüez I, et al. Among authors: brosa m. Ann Hepatol. 2017 May-Jun;16(3):358-365. doi: 10.5604/16652681.1235478. Ann Hepatol. 2017. PMID: 28425405 Free article.

9

Cost-effectiveness analysis of different strategies for treating duodenal ulcer. Helicobacter pylori eradication versus antisecretory treatment.

Badia X, Segú JL, Ollé A, Brosa M, Monés J, García Ponte L. Badia X, et al. Among authors: brosa m. Pharmacoeconomics. 1997 Apr;11(4):367-76. doi: 10.2165/00019053-199711040-00008. Pharmacoeconomics. 1997. PMID: 10166411

10

Orphan drugs revisited: cost-effectiveness analysis of the addition of mifamurtide to the conventional treatment of osteosarcoma.

Brosa M, García del Muro X, Mora J, Villacampa A, Pozo-Rubio T, Cubells L, Montoto C. Brosa M, et al. Expert Rev Pharmacoecon Outcomes Res. 2015 Apr;15(2):331-40. doi: 10.1586/14737167.2015.972378. Epub 2014 Oct 29. Expert Rev Pharmacoecon Outcomes Res. 2015. PMID: 25354299

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

56 results

Search Page

Filters